2013-05-20 13:03:03 -
Backed by Robust Clinical Data on Broad Product Family,
New Thrombus Removal System Offers Superior Deliverability
MINNEAPOLIS -- May 20, 2013 -- Expanding its portfolio of medical technology for
the interventional treatment of cardiovascular disease, Medtronic, Inc. (NYSE:
MDT) announced today that the Export Advance aspiration catheter recently
received the CE (Conformité Européenne) mark and will soon be launched in Europe
and other international markets.
The new thrombus removal system from the market leader in the product category
offers superior deliverability en route to the aspiration site. The Export
Advance aspiration catheter is not approved for use in the United States. The
latest addition to the Export family of aspiration catheters will be on exhibit
during EuroPCR (May 21-24 in
Paris) at the Medtronic booth.
"When thrombus completely or partially blocks an artery, aspiration is an
important first step of the treatment process that can improve clinical
outcomes," said Dr. Sanjit Jolly, an associate professor of cardiology at
Canada's McMaster University in Hamilton, Ontario, and an interventional
cardiologist at Hamilton Health Sciences.
"Removing thrombus with highly effective aspiration catheters, such as those in
the Export family, is especially critical when faced with a patient having a
heart attack in order to access the lesion quickly and restore blood flow as
soon as possible."
Dr. Jolly serves as a principal investigator of the TOTAL study (a randomized
trial of routine aspiration ThrOmbecTomy with PCI versus PCI ALone in patients
with STEMI undergoing primary PCI), which has an enrollment target of 6,000
patients across approximately 70 sites worldwide. Export aspiration catheters
are the only devices being used in the TOTAL study.
A new feature of the Export Advance aspiration catheter is a pre-loaded stylet,
a core wire that runs through the middle of the shaft to provide more support
during delivery. This feature increases the deliverability and kink resistance
of the device when traversing the anatomy to reach the aspiration site. The
Export Advance aspiration catheter is also constructed with full-wall variable
braiding technology that provides variable levels of stiffness along the length
of the device to enhance flexibility and pushability for optimal catheter
"With more than 10 years of market leadership in this product category,
Medtronic has continued to lead the way in innovation, setting a new standard of
performance with the Export Advance aspiration catheter," said Jason Weidman,
vice president and general manager of Medtronic's coronary business. "In
addition to superior deliverability, our next-generation device offers high-
performing aspiration power that physicians have come to expect from Export
aspiration catheters, which to date have been used to treat more than one
million patients worldwide."
Use of aspiration has dramatically increased worldwide since 2008 when The New
England Journal of Medicine published results of a randomized clinical trial
("Thrombus Aspiration during Percutaneous coronary intervention in Acute
myocardial infarction Study"). Conducted at University Medical Center Groningen
in the Netherlands and involving nearly 1,100 subjects, TAPAS showed that
patients treated with the Export family of aspiration catheters prior to
coronary stenting demonstrated a statistically significant reduction in cardiac
death at one year compared to those who did not receive aspiration.()
TASTE (Thrombus Aspiration in Myocardial Infarction) is a more recent study of
aspiration. Involving approximately 25 sites in Scandanavia (Denmark, Iceland
and Sweden), it randomized more than 7,200 heart attack patients to receive
conventional percutaneous coronary intervention (PCI) with or without manual
aspiration thrombectomy and has a primary endpoint of time to all-cause
mortality at 30 days. Export aspiration catheters were among the devices used in
the TASTE trial, which Medtronic supported with an unrestricted research grant.
Results from this study will likely be presented later this year.
In collaboration with leading clinicians, researchers and scientists worldwide,
Medtronic offers the broadest range of innovative medical technology for the
interventional and surgical treatment of cardiovascular disease and cardiac
arrhythmias. The company strives to offer products and services that deliver
clinical and economic value to healthcare consumers and providers around the
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global
leader in medical technology -- alleviating pain, restoring health and extending
life for millions of people around the world.
Any forward-looking statements are subject to risks and uncertainties such as
those described in Medtronic's periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from anticipated
- end -
 Svilaas T., Vlaar P.J., van der Horst I.C., Diercks G. F., de Smet B.J., van
den Heuvel A. F., et al.(2008). Thrombus Aspiration during Primary Percurtaneous
Coronary Intervention. The New England Journal of Medicine, 358(6), 557-67.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Medtronic, Inc. via Thomson Reuters ONE